Up-regulation of VEGF and Its Receptor in Refractory Leukemia Cells

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Jul 21

PMID 26191229

Citations 12

Authors

Lei Wang

Wenjun Zhang

Yi Ding

Bing Xiu

Ping Li

Yan Dong

Qi Zhu

Aibin Liang

Affiliations

Soon will be listed here.

Abstract

Objective: To analyze the causative mechanisms in refractory leukemia cells.

Methods: Vascular endothelial growth factor (VEGF) blood plasma concentrations in 35 de novo, 6 relapse, 20 remission leukemia patients and 10 healthy kids were determined via ELISA analyses. Transcription levels of the VEGF receptors (VEGFR) Fms-like tyrosine kinase-1 (Flt-1) and kinase-domain insert containing receptor (KDR) were determined in participants' leucocytes with RT-PCR. Apoptosis rates as well as Cyt-C and Caspase-3 expression was determined in Jurkat, Jurkat(Bcl-2), healthy and recurrent leukemia leukocytes with and without VP-16 applications via flow cytometry. Total Akt (t-Akt) expression and its phosphorylation (p-AKT) status in leukocytes of the participants were analyzed with western blots.

Results: Healthy children and the remission group had the lowest blood plasma VEGF concentrations (91.16±41.34 vs. 135.80±111.28 pg/ml), followed by de novo leukemia patients (362.49±195.68 pg/ml-494.19±186.23 pg/ml) and relapse patients (574.37±278.45 pg/ml) (P<0.01). The same trend was statistically significant visible for Flt-1 and KDR expressions in leukocytes of the participants. Stable Bcl-2 overexpression led to reduced apoptosis rates as well as Cyt-C and Caspase-3 expressions in Jurkat cells after VP-16 application, which was similar in leucocytes of remission patients. In contrast to no phosphorylation in healthy children, Akt was phosphorylated in 10% remission samples, 30% de novo leukemia samples and in 67% of recurrent leukemia leucocytes.

Conclusion: High VEGF plus VEGFR expression and AKT phosphorylation are highest in leukocytes of remission patients, suggesting VEGF signaling as a cause of reduced apoptosis susceptibility upon treatments.

Citing Articles

Bioactive Phytoconstituents and Their Therapeutic Potentials in the Treatment of Haematological Cancers: A Review.

Iweala E, Oluwapelumi A, Dania O, Ugbogu E Life (Basel). 2023; 13(7).

PMID: 37511797 PMC: 10381774. DOI: 10.3390/life13071422.

Neuropilin (NRPs) Related Pathological Conditions and Their Modulators.

Broz M, Kolaric A, Jukic M, Bren U Int J Mol Sci. 2022; 23(15).

PMID: 35955539 PMC: 9368954. DOI: 10.3390/ijms23158402.

Molecular effects of genistein, as a potential anticancer agent, on CXCR-4 and VEGF pathway in acute lymphoblastic leukemia.

Shahmoradi M, Banisharif-Dehkordi F, Kouhihabibidehkordi M, Ghatrehsamani M, Jami M, Shirzad H Mol Biol Rep. 2022; 49(6):4161-4170.

PMID: 35608747 DOI: 10.1007/s11033-022-07163-0.

Baohuoside I Inhibits Tumor Angiogenesis in Multiple Myeloma the Peroxisome Proliferator-Activated Receptor γ/Vascular Endothelial Growth Factor Signaling Pathway.

Chen Y, Zhang L, Zang X, Shen X, Li J, Chen L Front Pharmacol. 2022; 13:822082.

PMID: 35341213 PMC: 8948427. DOI: 10.3389/fphar.2022.822082.

Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features.

Gutierrez L, Valenzuela Alvarez M, Yang Y, Spinelli F, Cantero M, Alaniz L Apoptosis. 2021; 26(7-8):447-459.

PMID: 34024019 DOI: 10.1007/s10495-021-01677-x.

References

West K, Castillo S, Dennis P . Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2003; 5(6):234-48. DOI: 10.1016/s1368-7646(02)00120-6. View

Broggini M, Marchini S, Galliera E, Borsotti P, Taraboletti G, Erba E . Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia. 2003; 17(1):52-9. DOI: 10.1038/sj.leu.2402788. View

Xu Q, Simpson S, Scialla T, Bagg A, Carroll M . Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003; 102(3):972-80. DOI: 10.1182/blood-2002-11-3429. View

Fulda S, Debatin K . Apoptosis pathways in neuroblastoma therapy. Cancer Lett. 2003; 197(1-2):131-5. DOI: 10.1016/s0304-3835(03)00091-0. View

Stahnke K, Eckhoff S, Mohr A, Meyer L, Debatin K . Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells. Leukemia. 2003; 17(11):2130-9. DOI: 10.1038/sj.leu.2403144. View

Thomas D, Estey E, Giles F, Faderl S, Cortes J, Keating M . Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 2003; 123(3):436-41. DOI: 10.1046/j.1365-2141.2003.04639.x. View

Usnarska-Zubkiewicz L, Mazur G, Wrobel T, Poreba M, Kuliczkowski K . [Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma]. Pol Arch Med Wewn. 2003; 110(1):719-24. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

Manabe A, Coustan-Smith E, Kumagai M, Behm F, Raimondi S, Pui C . Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood. 1994; 83(7):1731-7. View

10.

Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand A . Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996; 92(1):97-103. DOI: 10.1046/j.1365-2141.1996.00305.x. View

11.

Brown L, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe M . Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest. 1997; 76(2):245-55. View

12.

Gerber H, McMurtrey A, Kowalski J, Yan M, Keyt B, Dixit V . Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998; 273(46):30336-43. DOI: 10.1074/jbc.273.46.30336. View

13.

Katoh O, Takahashi T, Oguri T, Kuramoto K, Mihara K, Kobayashi M . Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res. 1998; 58(23):5565-9. View

14.

Bellamy W, Richter L, Frutiger Y, Grogan T . Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999; 59(3):728-33. View

15.

Kessler T, Fehrmann F, Bieker R, Berdel W, Mesters R . Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Curr Drug Targets. 2007; 8(2):257-68. DOI: 10.2174/138945007779940089. View

16.

Malladi S, Challa-Malladi M, Fearnhead H, Bratton S . The Apaf-1*procaspase-9 apoptosome complex functions as a proteolytic-based molecular timer. EMBO J. 2009; 28(13):1916-25. PMC: 2711187. DOI: 10.1038/emboj.2009.152. View

17.

Song G, Li Y, Jiang G . Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review). Oncol Rep. 2012; 28(6):1935-44. DOI: 10.3892/or.2012.2045. View

18.

Kampen K, Ter Elst A, de Bont E . Vascular endothelial growth factor signaling in acute myeloid leukemia. Cell Mol Life Sci. 2012; 70(8):1307-17. PMC: 11113417. DOI: 10.1007/s00018-012-1085-3. View

19.

Kutsch N, Hallek M, Eichhorst B . Emerging therapies for refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2014; 56(2):285-92. DOI: 10.3109/10428194.2014.917641. View

20.

Jones R, Parsons M, Bonnard M, Chan V, Yeh W, Woodgett J . Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med. 2000; 191(10):1721-34. PMC: 2193154. DOI: 10.1084/jem.191.10.1721. View